导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 11.03% | 32/108 |
| 近一周 | -3.64% | 80/115 |
| 近一月 | -1.44% | 18/119 |
| 近一季 | -2.73% | 46/117 |
| 近半年 | 7.47% | 36/111 |
| 近一年 | 11.77% | 29/99 |
| 近两年 | 39.79% | 62/94 |
| 近三年 | 46.48% | 38/74 |
| 成立以来 | 21.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.96% 63/109 |
15.60% 40/119 |
- - |
- - |
| 2025 | 22.48% 69/108 |
2.62% 62/97 |
9.10% 59/99 |
9.50% 90/104 |
-0.10% 36/108 |
| 2024 | 7.98% 58/97 |
1.13% 51/89 |
5.87% 29/94 |
5.96% 55/97 |
-4.82% 70/97 |
| 2023 | 2.36% 24/93 |
2.11% 28/73 |
3.97% 21/77 |
-7.24% 66/82 |
3.93% 31/93 |
| 2022 | -10.14% 9/71 |
-6.61% 5/58 |
-5.58% 49/62 |
-9.54% 15/68 |
12.65% 17/71 |
| 2021 | -12.10% 21/58 |
- 202/312 |
0.09% 242/328 |
-8.33% 209/358 |
-4.20% 18/58 |
| 2020 | 27.74% 20/38 |
-17.37% 202/280 |
21.58% 91/295 |
7.31% 72/299 |
18.49% 27/305 |
| 2019 | 23.81% 16/30 |
9.52% 134/258 |
1.45% 135/268 |
0.65% 123/253 |
10.71% 56/266 |
| 2018 | -13.38% 8/28 |
- - |
- - |
- - |
-10.58% 116/241 |
| 2017 | 31.58% 8/20 |
- - |
- - |
- - |
- - |
| 2016 | 7.42% 5/17 |
- - |
- - |
- - |
- - |
| 2015 | -2.58% 6/16 |
- - |
- - |
- - |
- - |
| 2014 | 0.69% 59/99 |
- - |
- - |
- - |
- - |
| 2013 | -0.69% 46/70 |
- - |
- - |
- - |
- - |
| 2012 | 14.82% 18/51 |
- - |
- - |
- - |
- - |
| 2011 | -26.88% 26/27 |
- - |
- - |
- - |
- - |
| 2010 | 14.00% 1/9 |
- - |
- - |
- - |
- - |
| 2009 | 58.49% 4/9 |
- - |
- - |
- - |
- - |
| 2008 | -56.82% 3/3 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 摩根中国生物医药混合(QDII)A | 1.4779 | 17.64% |
| 摩根中国生物医药混合(QDII)C | 1.4554 | 17.49% |
| 南方港股医药行业混合发起(QDII)A | 1.3423 | 15.29% |
| 南方港股医药行业混合发起(QDII)C | 1.2936 | 15.12% |
| 东方红医疗创新混合(QDII)A | 0.8769 | 15.09% |
| 东方红医疗创新混合(QDII)C | 0.8725 | 13.42% |
| 万家全球成长一年持有期混合(QDII)A | 0.9681 | 12.64% |
| 万家全球成长一年持有期混合(QDII)C | 0.9395 | 12.46% |
| 长城港股医疗保健精选混合发起(QDII)A | 0.7593 | 8.70% |
| 富国医药精选混合(QDII)A | 0.9730 | 8.69% |
| 摩根亚太优势混合(QDII)A VS. 建信新兴市场混合(QDII)A(539002) |